anti-Nipah_175
| anti-Nipah_ID | anti-Nipah_175 |
| anti-Nipah Drug | 4-amino-1-[5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
| Nipah virus strain | NiV (Rec. M-GFP2AM ) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | NCI-H358 cells or SAECs |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 0.25-0.5 TCID50 |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Pre infection 1 hour |
| Duration of Drug delivery for anti-Nipah activity | 48-168 hours |
| Drug concentration used to test anti-Nipah activity | 3.1 ? 0.36 μM |
| Assays used to test anti-Nipah activity | Fluorescence |
| anti-Nipah activity | Decrease [Effective concentration (50 %)] |
| References | Lo MK, Jordan PC, Stevens S, Tam Y, Deval J, Nichol ST, Spiropoulou CF. Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs. Antiviral Res. 2018 May;153:101-113. doi: 10.1016/j.antiviral.2018.03.009 |
| Comments | The enhanced antiviral activity was observed against paramyxoviruses with both 2'diF-4'N3-C and 2'F-4'N3-C compared to R1479. The activity of these compounds against negative-strand RNA viruses endorses the development of 4'-modified nucleoside analogs as broad-spectrum therapeutics against zoonotic viruses of public health importance. |